These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8587923)

  • 1. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze.
    Rodgers RJ; Cole JC; Aboualfa K; Stephenson LH
    Pharmacol Biochem Behav; 1995 Dec; 52(4):805-13. PubMed ID: 8587923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: predictive validity and sensitivity to anxiogenic agents.
    Jones N; Duxon MS; King SM
    Psychopharmacology (Berl); 2002 May; 161(3):314-23. PubMed ID: 12021835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat.
    Cole BJ; Hillmann M; Seidelmann D; Klewer M; Jones GH
    Psychopharmacology (Berl); 1995 Sep; 121(1):118-26. PubMed ID: 8539336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of a plus-maze to measure anxiety in the mouse.
    Lister RG
    Psychopharmacology (Berl); 1987; 92(2):180-5. PubMed ID: 3110839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethopharmacological analysis of rat behavior on the elevated plus-maze.
    Cruz AP; Frei F; Graeff FG
    Pharmacol Biochem Behav; 1994 Sep; 49(1):171-6. PubMed ID: 7816869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice.
    Kliethermes CL; Finn DA; Crabbe JC
    Psychopharmacology (Berl); 2003 Sep; 169(2):190-7. PubMed ID: 12783153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation.
    Varty GB; Morgan CA; Cohen-Williams ME; Coffin VL; Carey GJ
    Neuropsychopharmacology; 2002 Sep; 27(3):357-70. PubMed ID: 12225693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Carboline and pentylenetetrazol effects on conflict behavior in the rat.
    Hill TJ; Fontana DJ; McCloskey TC; Commissaris RL
    Pharmacol Biochem Behav; 1992 Aug; 42(4):733-6. PubMed ID: 1513854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state?
    File SE; Zangrossi H
    Psychopharmacology (Berl); 1993; 110(1-2):240-4. PubMed ID: 7870892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural effects of anxiogenic agents in the common marmoset.
    Carey GJ; Costall B; Domeney AM; Jones DN; Naylor RJ
    Pharmacol Biochem Behav; 1992 May; 42(1):143-53. PubMed ID: 1528937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory.
    Wall PM; Messier C
    Psychopharmacology (Berl); 2002 Mar; 160(3):233-44. PubMed ID: 11889492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of benzodiazepine inverse agonist FG 7142-induced anxiety syndrome by neurosteroids in mice.
    Reddy DS; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):665-81. PubMed ID: 9542718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative anxiety-linked effects of the nitric oxide synthase inhibitor L-NAME in three murine exploratory behavior models.
    Czech DA; Jacobson EB; LeSueur-Reed KT; Kazel MR
    Pharmacol Biochem Behav; 2003 Jul; 75(4):741-8. PubMed ID: 12957214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
    Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
    Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents.
    Chaki S; Kawashima N; Suzuki Y; Shimazaki T; Okuyama S
    Eur J Pharmacol; 2003 Mar; 464(1):49-54. PubMed ID: 12600694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls.
    Thiébot MH; Soubrié P; Sanger D
    Psychopharmacology (Berl); 1988; 94(4):452-63. PubMed ID: 3131790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium phenobarbitone reverses the anxiogenic effects of compounds acting at three different central sites.
    Johnston AL; File SE
    Neuropharmacology; 1989 Jan; 28(1):83-8. PubMed ID: 2538770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FG7142, yohimbine, and βCCE produce anxiogenic-like effects in the elevated plus-maze but do not affect brainstem activated hippocampal theta.
    Yeung M; Lu L; Hughes AM; Treit D; Dickson CT
    Neuropharmacology; 2013 Dec; 75():47-52. PubMed ID: 23851259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with imipramine does not reverse the effects of 3 anxiogenic compounds in a test of anxiety in the rat.
    File SE; Johnston AL
    Neuropsychobiology; 1987; 17(4):187-92. PubMed ID: 2894617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze.
    Anseloni VZ; Brandão ML
    Behav Pharmacol; 1997 Nov; 8(6-7):533-40. PubMed ID: 9832967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.